Managing Directors of L.E.K. Consulting, Joe Johnson, Todd Clark and Brendan Mitchell introduce the innovations happening in pharmacy, more specifically disruptive innovations, and how they affect managed care. The team explained some of the innovations to be on the lookout for in the future, also.
Managing Directors of L.E.K. Consulting, Joe Johnson, Todd Clark and Brendan Mitchell introduce the innovations happening in pharmacy, more specifically disruptive innovations, and how they affect managed care. The team explained some of the innovations to be on the lookout for in the future, also.
Johnson explained the pharmacy market has worked continuosly to tackle affortability and access issues, especially through price transparency, for better patient adherence.
"I think the other thing that's changed in the ecosystem is that we're trying to empower the physician to have more data at the point of care in order to make informed decisions around real time benefits and what's covered. So, that ultimately, the patient can have greater affordability and therefore coverage, lower out of pocket costs, lower co pays associated with with the pharmacy scripts that they'll be filling," he said. "Then also at the point of care, I think, helping steer the patient to the right pharmacies that will have the product to be filled immediately, as opposed to having to wait to start treatment."
Clark added disruptive innovations are working their way into pharmacy care as you see new pharmacy developments like Amazon and Mark Cuban's Cost Plus Drug Company.
These two organizations are examples of disruptive innovations in pharmacy as they aim to serve larger populations like people or large number of paying entities. The entities can include middle-market, self-insured employers, or where the dollars are in specialty pharmacy, Clark added.
"The thing about Specialty Pharmacy is it really is specialty by specialty, therapeutic area by therapeutic area, disease state by disease state," Clark said. "That game is won by building those on top of each other and winning one hand at a time."
Innovations the LEK team are anticipating focus on the lower-end of the self-funded employer market.
"I think we we may be entering a part of the economic cycle where cost sensitivity goes up and employers are more interested in than ever in looking at innovative models that can ultimately help manage costs (and) keep their employees healthy," Mitchell said. "Sometimes, with a difficult downturn, there's a lot of innovation on the edges it's something to keep an eye on."
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
Are Value-Based Contracts the Answer to Ultra-High-Priced Gene Therapies? | AMCP 2024
April 17th 2024Innovative contracts are becoming more common for gene therapies. They aim to balance a therapy’s cost-effectiveness and affordability, as well as address the uncertainty of long-term benefit.
Read More